MIA’s Justin Karter interviews critical psychiatrist and philosopher Pat Bracken about the necessity of challenging received wisdom.
MIA’s Ayurdhi Dhar interviews Diana Kopua about the Mahi a Atua approach, the global mental health movement, and the importance of language and narratives in how we understand our world and ease our suffering.
MIA's Zenobia Morrill interviews Lucy Johnstone about the reaction to the Power Threat Meaning Framework, her life influences, and her hopes for the future.
MIA’s Tim Beck interviews Dr. Felicity Thomas and Dr. Richard Byng about their report, Poverty, Pathology, and Pills, which situates increasing rates of mental health diagnosis and psychiatric prescriptions within socioeconomic and policy trends across the UK.
MIA's Gavin Crowell-Williamson interviews PharmedOut founder Dr. Adriane Fugh-Berman about Big Pharma's influence on medical education.
MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.
Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.
Dr. Raskin discusses psychotherapists’ dissatisfaction with current psychiatric diagnostic systems and explores alternatives.
Dr. Vance Trudeau discusses his study's finding that antidepressants may have far-reaching, adverse effects that last up to three generations.
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
Dr. Gail Hornstein, author of Agnes’s Jacket: A Psychologist’s Search for the Meanings of Madness, discusses the importance of personal narratives and service-user activism in the context of the global mental health movement.
Tony Kendrick, a professor of Primary Care at the University of Southampton, has found through his research and practice that too many people are being prescribed antidepressants long-term without the information and support necessary to get off of them.
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.
12Page 2 of 2